Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4272461 | 0.82 | AOC3 (0.42) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL2196089 | 0.80 | AOC3 (0.42) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL5064894 | 0.75 | ALDH1A1 (0.52) | MEN1KMT2AALDH1A1KDM4EEPHX2 | |
| Chloromethane SCHEMBL29855624 | 0.72 | HSD17B10 (0.59) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL249524 | 0.72 | HSD17B10 (0.63) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL247742 | 0.72 | HSD17B10 (0.63) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL2672977 | 0.72 | HSD17B10 (0.63) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL4459970 | 0.70 | HSD17B10 (0.61) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL9718520 | 0.70 | HSD17B10 (0.61) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL17571990 | 0.69 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | MEN1 3180/4885KMT2A 904/4885ALDH1A1 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.